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No Cause for Fear in Clinical PracticeWe read with great interest the work by Bonello et al. (1). The
authors are to be commended for a very elegant study of acute
coronary syndrome (ACS) patients demonstrating an increase in
adenosine plasma concentration (APC) by ticagrelor compared to
clopidogrel through inhibition of adenosine uptake by red blood
cells and supporting the hypothesis of signiﬁcant off-target prop-
erties of ticagrelor. Although not speciﬁcally addressed in the
present study, increases in APC may represent an additional an-
tiplatelet mechanism for ticagrelor (2). More importantly, ﬁndings
by Bonello et al. (1) provide a causative, missing link for the dif-
ferential effects of ticagrelor versus those of prasugrel on coronary
blood ﬂow velocity (CBFV) during increasing doses of intrave-
nously administered adenosine, as reported by our group in 56 ACS
patients (3). Although the APC increase was described in blood
samples obtained 6 h post-antiplatelet loading, one could speculate
a higher availability of adenosine while receiving treatment with
ticagrelor rather than the prasugrel maintenance dose (MD), as
implicated for CBFV observed differences, and partially explaining
the long-term beneﬁcial effects seen with ticagrelor.
However, we strongly disagree with characterization of the use of
adenosine as a provocative test in patients taking ticagrelor as
“coronary ﬂow reserve (CFR) with a turbo” by Voci and Pizzuto
(4). No CFR differences have been observed in healthy male
subjects given 180 mg of ticagrelor or in ACS patients given MD
of ticagrelor compared with placebo or MD of prasugrel, respec-
tively (3,5). Differences in [maximum CBFV/baseline CBFV] in
favor of ticagrelor were apparent with incremental adenosine doses
but not at the highest infusion rate of maximal hyperemia. Voci and
Pizzuto (4) hypothesized that patients receiving either ticagrelor or
dipyridamole might have a supernormal response to standard
adenosine doses used for both therapeutic and diagnostic applica-
tions, and suggested that we may have to reduce the initial aden-
osine dose 4- to 5-fold. Both ticagrelor and dipyridamole may be
equilibrative nucleoside transporter 1 (ENT1) inhibitors but are not
the “same” (2). Dipyridamole is a much more potent inhibitor than
ticagrelor. When adenosine (7.1 mmol l-1) is added to whole blood,
it is detectable for 3 to 6 min and for >60 min in the presence
of ticagrelor or dipyridamole, respectively (2). In the case of tica-
grelor, the suggested 4- to 5-fold dose reduction of adenosine
(ie, <50 mg/kg/min) would result in 35% to 45% of maximal CBFVseen at peak hyperemia (3,5). Voci and Pizzuto (4) warn against the
use of adenosine as a provocative test in ticagrelor-treated patients,
which in our opinion, is not supported by available evidence. At
peak hyperemia, mean arterial pressure, heart rate, and double
product did not differ between ticagrelor- and prasugrel-treated
patients (3). Adenosine-induced dyspnea is indeed signiﬁcantly
augmented with ticagrelor on board, although it is self-limiting and
of questionable clinical relevance. Moreover, the asymptomatic,
transient, second-degree atrioventricular block that does not need
medical treatment observed infrequently during adenosine infusions
may be slightly more common in subjects taking ticagrelor (3,5).
We believe that the increased APC described in patients with
ACS given ticagrelor should not raise any evidence-based concern
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We read with interest the letter by Drs. Alexopoulos and Xantho-
poulou regarding our study published in the Journal (1) and the letter
by Voci and Pizzuto (2). In that study we demonstrated that in acute
coronary syndrome patients, ticagrelor was associated with a signiﬁ-
cant increase in adenosine plasma level through inhibition of reuptake
by red blood cells. This interesting property of the drug, beyond
P2Y12-ADP receptor blockade, may be of clinical signiﬁcance.
